Yogurt Gastrointestinal Upset Reduction Trial for Children on Antibiotics

In children between the age of 1-12 presenting to General Practice who are prescribed oral antibiotics does yogurt with live cultures compared to pasteurised yogurt reduce the incidence of gastrointestinal disturbance as measured by stool frequency and consistency.

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12609000281291

Acronym

YoGURT for kids on antibiotics

Enrollment

Registered

2009-05-15

Start date

2009-09-20

Completion date

2012-08-14

Last updated

2020-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study aims to assess if yogurt (containing the probiotics LGG, Bb12 and La5) can reduce the incidence of gastro-intestinal upset associated with antibiotics administration in children aged 1-12

Interventions

This is a double-blind, randomized, placebo-controlled clinical trial intended to evaluate if the use of Vaalia yogurt containing Lactobacillus rhamnosus (LGG), Bifidobacterium lactis Bb-12 (Bb-12) and Lactobacillus acidophilus La-5 (La-5) compared to pasteurised yogurt reduces the incidence of gastrointestinal disturbance in children aged between 1-12 who are on oral antibiotics. Children will be given 100g of Vaalia yogurt 2/day commencing the same day that they start their antibiotic treatme

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Prevention

Masking

Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

All

Age

1 Years to 12 Years

Healthy volunteers

Yes

Inclusion criteria

Children between the age of 1 and 12 prescribed oral antibiotics

Exclusion criteria

Children will be excluded if they have a history of milk allergy or intolerance, antibiotic treatment within the previous 2 months, prophylactic antibiotic treatment, use of a probiotic product for medicinal purposes within the previous 7 days, immunodeficiency, chronic gastrointestinal disease and acute or chronic diarrhoea

Outcome results